PSY38 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 400mg Daily in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML)

Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.572
https://www.valueinhealthjournal.com/article/S1098-3015(12)00637-7/fulltext
Title : PSY38 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 400mg Daily in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)00637-7&doi=10.1016/j.jval.2012.03.572
First page : A105
Section Title : Systemic Disorders/Conditions
Open access? : No
Section Order : 38
Categories :
Tags :
Regions :
ViH Article Tags :